Your browser is no longer supported. Please, upgrade your browser.
Settings
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.50 Insider Own7.60% Shs Outstand43.83M Perf Week6.42%
Market Cap6.05B Forward P/E- EPS next Y-8.91 Insider Trans-17.45% Shs Float39.40M Perf Month11.82%
Income-259.00M PEG- EPS next Q-2.03 Inst Own- Short Float12.60% Perf Quarter37.63%
Sales2.40M P/S2520.33 EPS this Y-78.70% Inst Trans1.26% Short Ratio12.17 Perf Half Y45.75%
Book/sh13.80 P/B9.99 EPS next Y-4.80% ROA-52.00% Target Price125.00 Perf Year50.87%
Cash/sh14.72 P/C9.37 EPS next 5Y- ROE-57.00% 52W Range66.01 - 138.73 Perf YTD7.00%
Dividend- P/FCF- EPS past 5Y-11.90% ROI- 52W High-0.61% Beta1.76
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low108.88% ATR6.06
Employees111 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)67.18 Volatility6.06% 4.60%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.70% Profit Margin- Rel Volume0.88 Prev Close137.88
ShortableYes LT Debt/Eq0.00 EarningsAug 17 BMO Payout- Avg Volume407.90K Price137.88
Recom1.80 SMA2010.47% SMA5017.70% SMA20037.16% Volume0 Change0.00%
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Mar-12-20Upgrade JP Morgan Underweight → Neutral $88
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Aug-14-20 08:00AM  
Aug-13-20 08:03AM  
Aug-12-20 09:57AM  
Aug-06-20 04:15PM  
Aug-04-20 12:32PM  
08:00AM  
08:00AM  
Aug-03-20 10:18AM  
Aug-02-20 06:53PM  
Jul-31-20 09:31AM  
Jul-30-20 01:09PM  
11:08AM  
10:32AM  
08:28AM  
Jul-29-20 04:45PM  
04:01PM  
02:40PM  
Jul-27-20 12:31PM  
Jul-15-20 08:00AM  
Jul-14-20 12:50PM  
Jul-10-20 08:48PM  
Jul-06-20 04:52PM  
Jun-17-20 11:00AM  
Jun-16-20 10:09AM  
Jun-12-20 11:54AM  
Jun-06-20 11:31AM  
Jun-05-20 09:00AM  
Jun-03-20 09:45AM  
Jun-02-20 08:59PM  
Jun-01-20 09:07AM  
May-18-20 04:15PM  
12:13AM  
May-15-20 08:06PM  
12:04PM  
09:19AM  
09:00AM  
May-07-20 08:00PM  
May-05-20 08:41AM  
May-04-20 01:36PM  
Apr-27-20 12:32PM  
Apr-22-20 02:15PM  
Apr-21-20 04:19PM  
12:18PM  
Apr-20-20 07:23AM  
07:00AM  
Mar-26-20 01:06PM  
Feb-27-20 10:43AM  
Feb-25-20 08:00AM  
Feb-19-20 10:35AM  
08:30AM  
Feb-15-20 11:30AM  
Jan-14-20 04:01PM  
Jan-09-20 10:00PM  
08:39AM  
Jan-08-20 04:03PM  
Jan-07-20 07:57AM  
Jan-06-20 04:30PM  
Jan-03-20 01:36PM  
Jan-02-20 04:30PM  
Dec-26-19 11:11AM  
Dec-19-19 10:09AM  
Dec-18-19 08:40AM  
Dec-13-19 07:00AM  
Dec-04-19 08:35PM  
Nov-09-19 06:15PM  
Nov-04-19 06:55PM  
04:15PM  
Nov-03-19 07:10AM  
Oct-29-19 07:32AM  
Oct-28-19 04:15PM  
04:15PM  
Oct-25-19 11:05AM  
Oct-23-19 04:45PM  
Oct-17-19 09:00AM  
Oct-16-19 04:22PM  
Oct-07-19 06:00AM  
Oct-01-19 09:09AM  
Sep-28-19 08:34AM  
Sep-09-19 10:10AM  
Sep-05-19 09:16PM  
Sep-04-19 09:15AM  
Aug-23-19 10:15PM  
09:38AM  
Aug-15-19 04:30PM  
Aug-05-19 04:15PM  
Jul-18-19 07:35AM  
Jul-10-19 05:53PM  
04:41PM  
07:17AM  
Jul-09-19 04:30PM  
Jul-02-19 07:29AM  
Jul-01-19 04:30PM  
Jun-30-19 08:00AM  
Jun-27-19 04:05PM  
Jun-25-19 08:30AM  
Jun-24-19 04:01PM  
09:43AM  
Jun-18-19 07:09AM  
Jun-14-19 08:41AM  
Jun-13-19 11:51AM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER BRUCE L ADirectorAug 11Option Exercise6.782,25015,2554,250Aug 13 04:03 PM
CARTER BRUCE L ADirectorAug 11Sale126.412,250284,4282,000Aug 13 04:03 PM
FUCHS HENRY JDirectorAug 10Option Exercise20.5410,000205,40012,000Aug 11 05:36 PM
FUCHS HENRY JDirectorAug 10Sale131.3810,0001,313,7832,000Aug 11 05:36 PM
Braslyn Ltd.10% OwnerJun 12Option Exercise0.00600,0066003,135,972Jun 16 05:03 PM
Braslyn Ltd.10% OwnerJun 12Sale69.00600,00041,400,0002,535,966Jun 16 05:03 PM
CARTER BRUCE L ADirectorMay 18Option Exercise6.784,00027,1206,000May 20 05:10 PM
CARTER BRUCE L ADirectorMay 18Sale106.864,000427,4402,000May 20 05:10 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Option Exercise24.9933,334833,01772,735May 13 04:18 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Sale105.0033,3343,500,07039,401May 13 04:18 PM
BAUM CHARLES MPresident & CEOApr 27Option Exercise5.405573,008107,023Apr 28 08:49 PM
Johnson Craig ADirectorApr 20Option Exercise25.8415,000387,60017,000Apr 21 05:26 PM
Johnson Craig ADirectorApr 20Sale93.0015,0001,395,0002,000Apr 21 05:26 PM
BAUM CHARLES MPresident & CEOApr 17Option Exercise8.4940,000339,600146,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOApr 17Sale90.3340,0003,613,109106,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOMar 27Option Exercise5.402,29112,371106,466Mar 30 05:52 PM
Christensen JamieEVP, Chief Scientific OfficerMar 26Option Exercise15.518,058124,98332,842Mar 27 05:37 PM
BAUM CHARLES MPresident & CEOFeb 28Option Exercise5.402,29112,371104,175Mar 02 04:28 PM
BAUM CHARLES MPresident & CEOFeb 04Option Exercise15.414,68772,247101,884Feb 06 04:41 PM
CHEN ISANEVP, Chief Medical OfficerJan 29Option Exercise24.993,00275,02039,401Jan 31 08:03 PM
Boxer Capital, LLC10% OwnerJan 10Buy97.5050,0004,875,0001,765,560Jan 14 04:30 PM
BAUM CHARLES MPresident & CEODec 24Option Exercise24.933187,92756,917Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Option Exercise5.446,66636,24613,326Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Sale125.006,666833,2509,159Dec 26 06:15 PM
CARTER BRUCE L ADirectorNov 20Option Exercise6.783,00020,3403,000Nov 22 04:46 PM
CARTER BRUCE L ADirectorNov 20Sale94.743,000284,2200Nov 22 04:46 PM
GREY MICHAEL GDirectorNov 12Option Exercise16.843,50058,9405,298Nov 14 06:30 PM
GREY MICHAEL GDirectorNov 12Sale102.443,042311,6222,256Nov 14 06:30 PM
BAUM CHARLES MPresident & CEOAug 22Option Exercise8.6752,368454,290117,851Aug 23 06:07 PM
BAUM CHARLES MPresident & CEOAug 22Sale86.2251,8104,467,31266,041Aug 23 06:07 PM
CARTER BRUCE L ADirectorAug 21Option Exercise6.783,00020,3403,000Aug 23 06:01 PM
CARTER BRUCE L ADirectorAug 21Sale89.243,000267,7200Aug 23 06:01 PM